ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
35.22
-0.93%
US Tech 100
18,488.00
-0.25%
S&P 500
5,346.99
-0.11%
US Dollar vs CAD
1.37725
-0.03%
Bitcoin
69,314.33
-0.03%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Lipocine Inc (LPCN)

  7. Lipocine Inc (LPCN) News

LPCN

Lipocine (LPCN)

Lipocine Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:LPCN
DateTimeSourceHeadlineSymbolCompany
06/07/20244:48PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/07/20244:45PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/07/20244:43PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/07/20244:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/07/20244:39PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:LPCNLipocine Inc
06/05/20243:32PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
06/03/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
06/03/20244:09PMEdgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:LPCNLipocine Inc
05/09/20247:00AMPR Newswire (US)Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024NASDAQ:LPCNLipocine Inc
05/09/20245:06AMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:LPCNLipocine Inc
05/09/20245:03AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
05/08/20247:00AMPR Newswire (US)Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024NASDAQ:LPCNLipocine Inc
05/08/20245:15AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
05/01/20247:00AMPR Newswire (US)Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154NASDAQ:LPCNLipocine Inc
04/11/20246:00AMPR Newswire (US)Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityNASDAQ:LPCNLipocine Inc
03/28/20247:00AMPR Newswire (US)Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisNASDAQ:LPCNLipocine Inc
03/25/20247:00AMPR Newswire (US)Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
03/07/20244:31PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
03/07/20247:00AMPR Newswire (US)Lipocine Announces Financial Results for the Full Year Ended December 31, 2023NASDAQ:LPCNLipocine Inc
03/07/20245:08AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
03/07/20245:07AMEdgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:LPCNLipocine Inc
03/06/20247:00AMPR Newswire (US)Lipocine to Present at 36th Annual Roth ConferenceNASDAQ:LPCNLipocine Inc
03/06/20245:01AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
02/12/20243:10PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
02/06/20247:00AMPR Newswire (US)Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154NASDAQ:LPCNLipocine Inc
02/02/20247:00AMPR Newswire (US)Lipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsNASDAQ:LPCNLipocine Inc
01/18/20247:20AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
01/18/20247:00AMPR Newswire (US)Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and CanadaNASDAQ:LPCNLipocine Inc
12/19/20239:00AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:LPCNLipocine Inc
12/19/20237:00AMPR Newswire (US)Lipocine to Present at Biotech Showcase 2024NASDAQ:LPCNLipocine Inc
 Showing the most relevant articles for your search:NASDAQ:LPCN

Your Recent History

USOTC
GNCP
GNCC Capital (CE)
USOTC
GVSI
Good Vibrations Shoes (PK)
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
VPLM
Voip Pal Com (QB)
NASDAQ
COOP
Mr Cooper
USOTC
CYDY
CytoDyn (QB)
NASDAQ
NB
NioCorp Developments
USOTC
BIEL
Bioelectronics (PK)
USOTC
AXXA
Exxe (PK)
USOTC
UBQU
Ubiquitech Software (PK)
USOTC
RNVA
Rennova Health (PK)
USOTC
SMCE
SMC Entertainment (PK)
USOTC
RONN
Ronn Motor (PK)
USOTC
PHIL
PHI (PK)
USOTC
CLNV
Clean Vision (QB)
USOTC
NWBO
Northwest Biotherapeutics (QB)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved